See more : Rex Minerals Limited (RXRLF) Income Statement Analysis – Financial Results
Complete financial analysis of 2seventy bio, Inc. (TSVT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 2seventy bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Optimus Group Company Limited (9268.T) Income Statement Analysis – Financial Results
- Quaker Chemical Corporation (KWR) Income Statement Analysis – Financial Results
- ETS Group Limited (8031.HK) Income Statement Analysis – Financial Results
- Topindo Solusi Komunika Tbk. (TOSK.JK) Income Statement Analysis – Financial Results
- Belvoir Group PLC (BLV.L) Income Statement Analysis – Financial Results
2seventy bio, Inc. (TSVT)
About 2seventy bio, Inc.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 100.39M | 91.50M | 54.52M | 248.12M | 44.30M | 54.58M |
| Cost of Revenue | 16.92M | 26.22M | 12.59M | 5.40M | 2.98M | 885.00K |
| Gross Profit | 83.47M | 65.28M | 41.93M | 242.73M | 41.32M | 53.69M |
| Gross Profit Ratio | 83.15% | 71.34% | 76.91% | 97.83% | 93.28% | 98.38% |
| Research & Development | 230.76M | 248.74M | 261.94M | 296.47M | 297.65M | 200.49M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 69.41M | 79.45M | 93.51M | 90.90M | 81.65M | 53.63M |
| Other Expenses | 20.91M | 6.06M | 21.65M | 18.06M | 20.13M | 19.16M |
| Operating Expenses | 321.08M | 328.19M | 355.44M | 387.36M | 379.29M | 254.12M |
| Cost & Expenses | 317.09M | 354.40M | 368.03M | 392.76M | 382.27M | 255.01M |
| Interest Income | 12.41M | 2.93M | 88.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.49M |
| Depreciation & Amortization | 10.29M | 11.53M | 16.40M | 13.19M | 12.59M | 13.35M |
| EBITDA | -206.42M | -251.38M | -297.16M | -131.45M | -329.19M | -187.08M |
| EBITDA Ratio | -205.62% | -274.49% | -574.21% | -45.70% | -728.37% | -307.66% |
| Operating Income | -216.70M | -262.91M | -313.51M | -144.64M | -337.97M | -203.43M |
| Operating Income Ratio | -215.87% | -287.34% | -575.01% | -58.29% | -762.99% | -372.72% |
| Total Other Income/Expenses | -867.00K | 8.76M | 21.30M | 24.52M | 17.38M | 3.68M |
| Income Before Tax | -217.57M | -254.15M | -292.21M | -120.11M | -320.59M | -199.75M |
| Income Before Tax Ratio | -216.73% | -277.77% | -535.95% | -48.41% | -723.75% | -365.98% |
| Income Tax Expense | 0.00 | -8.99K | -16.00M | 18.06M | 2.75M | 19.16M |
| Net Income | -217.57M | -254.14M | -276.21M | -138.17M | -323.34M | -199.75M |
| Net Income Ratio | -216.73% | -277.77% | -506.61% | -55.69% | -729.96% | -365.98% |
| EPS | -4.42 | -7.13 | -11.71 | -5.93 | -13.88 | -8.58 |
| EPS Diluted | -4.42 | -7.13 | -11.71 | -5.93 | -13.88 | -8.58 |
| Weighted Avg Shares Out | 49.28M | 35.64M | 23.59M | 23.29M | 23.29M | 23.29M |
| Weighted Avg Shares Out (Dil) | 49.28M | 35.64M | 23.59M | 23.29M | 23.29M | 23.29M |
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that the Company will host a conference call on Tuesday, December 12, 2023, at 8:00am ET. The event will highlight data presented at the 65th...
Best Penny Stocks To Buy? 4 To Watch With Big News This Week
Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as their prices fluctuate wildly around key events.
2seventy bio Reiterates Commitment to Maximizing Shareholder Value
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (NASDAQ: TSVT), (“2seventy” or “the Company”), a leading immuno-oncology cell therapy company, today issued the following statement reiterating its commitment to maximizing shareholder value: As we indicated last month, the Board has commenced a process...
Engine Capital pushes for changes at cancer therapy developer 2seventy bio
Activist investor Engine Capital on Wednesday sent a letter to the board of cancer therapy developer 2seventy bio , urging a board refresh and the appointment of its chief operating officer Chip Baird as CEO, among other changes.
Engine Capital Sends Letter to 2seventy's Board of Directors Outlining Steps to Maximize Shareholder Value
NEW YORK--(BUSINESS WIRE)--Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (Nasdaq: TSVT) (“2seventy” or the “Company”) outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the “Board”). *** December 6, 2023...
Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug
Shares of Bristol-Myers Squibb (BMY) and partner 2seventy bio (TSVT) slumped after the two companies announced that the Food and Drug Administration (FDA) would not make a decision on expanded use for their blood cancer treatment, Abecma, next month as...
Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment
Shares of Bristol Myers Squibb Co. BMY and 2seventy bio Inc. TSVT fell premarket on Monday after the companies said the U.S. Food and Drug Administration would miss its target date for potential approval of earlier use of a cancer...
US FDA delays decision on Bristol Myers-2seventy bio cancer therapy
The U.S. Food and Drug Administration (FDA) will not make a decision on Bristol Myers Squibb and 2seventy bio's marketing application of their blood cancer therapy, Abecma, for earlier lines of treatment by Dec. 16.
2seventy bio, Inc. (TSVT) Loses -44.63% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2seventy bio, Inc. (TSVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal...
3 Biotech Stocks With Key Catalysts Coming in December
Some of the most exciting opportunities can be found in biotech stocks. In fact, find one with a powerful catalyst just around the corner, and you can make a good deal of money.
Source: https://incomestatements.info
Category: Stock Reports